Histone acetyltransferase inhibitors and preclinical studies

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 6, 2009, Pages 761-774

  Manzo, Fabio ^a   Tambaro, Francesco Paolo ^a,b   Mai, Antonello ^c   Altucci, Lucia ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF HOUSTON   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer disease; Cancer; Clinical trials; Epigenetics; HAT inhibitors; Patents

Indexed keywords

ANACARDIC ACID; CAPECITABINE; CELECOXIB; CURCUMIN; GARCINOL; GEMCITABINE; GINKGO BILOBA EXTRACT; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CATALYSIS; COLON CANCER; COLORECTAL CANCER; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG STRUCTURE; FAMILIAL POLYPOSIS; HUMAN; INTESTINE POLYP; IRRITABLE COLON; LICHEN PLANUS; MULTIPLE MYELOMA; OPTIC NERVE ATROPHY; OSTEOARTHRITIS; OSTEOSARCOMA; PANCREAS CANCER; PATENT; PSORIASIS; RECTUM CANCER; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CURCUMIN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HISTONE ACETYLTRANSFERASES; HUMANS; NEOPLASMS; PATENTS AS TOPIC;

EID: 67649379393     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902895727     Document Type: Review

References (93)

1. Altucci L, Stunnenberg HG. Time for epigenetics. Int J Biochem Cell Biol 2009;41(1):2-3 • General review about epigenetics, provided by two specialists of the field. It represents a nice introduction on this field.
2. Peters AH, Mermoud JE, O'Carroll D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet 2002;30(1):77-80 (Pubitemid 34886693)
3. Schotta G, Lachner M, Peters AH, Jenuwein T. The indexing potential of histone lysine methylation. Novartis Found Symp 2004;259:22-37; discussion -47, 163-169 (Pubitemid 41505167)
4. Brown CE, Lechner T, Howe L, Workman JL. The many HATs of transcription coactivators. Trends Biochem Sci 2000;25(1):15-19 (Pubitemid 30060424)
5. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-784 (Pubitemid 44348499)
6. Kimura A, Matsubara K, Horikoshi M. A decade of histone acetylation: marking eukaryotic chromosomes with specific codes. J Biochem 2005;138(6):647-662 (Pubitemid 43258858)
7. Grant PA, Duggan L, Cote J, et al. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. Genes Dev 1997;11(13):1640-1650 (Pubitemid 27300590)
8. Pray-Grant MG, Daniel JA, Schieltz D, et al. Chd1 chromodomain links histone H3 methylation with SAGA- and SLIK-dependent acetylation. Nature 2005;433(7024):434-438 (Pubitemid 40203325)
9. Martin DG, Grimes DE, Baetz K, Howe L. Methylation of histone H3 mediates the association of the NuA3 histone acetyltransferase with chromatin. Mol Cell Biol 2006;26(8):3018-3028
10. Wittschieben BO, Otero G, de Bizemont T, et al. A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme. Mol Cell 1999;4(1):123-128 (Pubitemid 29386138)
11. Dhalluin C, Carlson JE, Zeng L, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999;399(6735):491-496 (Pubitemid 29258857)
12. Joshi AA, Struhl K. Eaf3 chromodomain interaction with methylated H3-K36 links histone deacetylation to Pol II elongation. Mol Cell 2005;20(6):971-978 (Pubitemid 41814885)
13. Couture JF, Collazo E, Trievel RC. Molecular recognition of histone H3 by the WD40 protein WDR5. Nat Struct Mol Biol 2006;13(8):698-703 (Pubitemid 44175162)
14. Wysocka J, Swigut T, Milne TA, et al. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 2005;121(6):859-872 (Pubitemid 40806418)
15. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37(4):391-400 • The authors link the acetylation of H4K16 with cancer. A therapeutic possibility for HAT inhibitors is suggested. (Pubitemid 40490489)
16. Shogren-Knaak M, Ishii H, Sun JM, et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006;311(5762):844-847 (Pubitemid 43228847)
17. Akhtar A, Becker PB. Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila. Mol Cell 2000;5(2):367-375 (Pubitemid 30628093)
18. Smith ER, Cayrou C, Huang R, et al. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol 2005;25(21):9175-9188 (Pubitemid 41507821)
19. Meijsing SH, Ehrenhofer-Murray AE. The silencing complex SAS-I links histone acetylation to the assembly of repressed chromatin by CAF-I and Asf1 in Saccharomyces cerevisiae. Genes Dev 2001;15(23):3169-3182 (Pubitemid 33115680)
20. Osada S, Sutton A, Muster N, et al. The yeast SAS (something about silencing) protein complex contains a MYST-type putative acetyltransferase and functions with chromatin assembly factor ASF1. Genes Dev 2001;15(23):3155-3168 (Pubitemid 33115679)
21. Shia WJ, Osada S, Florens L, et al. Characterization of the yeast trimeric-SAS acetyltransferase complex. J Biol Chem 2005;280(12):11987-11994 (Pubitemid 40418516)
22. Suka N, Luo K, Grunstein M. Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat Genet 2002;32(3):378-383 (Pubitemid 35266111)
23. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo J 2000;19(6):1176-1179 • The role and the interchange of two well-studied post-translational modifications, (phosphorylation & acetylation) is discussed, giving a picture of the system complexity.
24. Frank SR, Schroeder M, Fernandez P, et al. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001;15(16):2069-2082 (Pubitemid 32762051)
25. Kenneth NS, Ramsbottom BA, Gomez-Roman N, et al. TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc Natl Acad Sci USA 2007;104(38):14917-14922 (Pubitemid 47619568)
26. Martinez-Balbas MA, Bauer UM, Nielsen SJ, et al. Regulation of E2F1 activity by acetylation. EMBO J 2000;19(4):662-671 (Pubitemid 30093739)
27. Marzio G, Wagener C, Gutierrez MI, et al. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 2000;275(15):10887-10892 (Pubitemid 30212722)
28. Lang SE, McMahon SB, Cole MD, Hearing P. E2F transcriptional activation requires TRRAP and GCN5 cofactors. J Biol Chem 2001;276(35):32627-32634 (Pubitemid 37384703)
29. Taubert S, Gorrini C, Frank SR, et al. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol 2004;24(10):4546-4556 (Pubitemid 44109137)
30. Oishi H, Kitagawa H, Wada O, et al. An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification. J Biol Chem 2006;281(1):20-26 (Pubitemid 43671158)
31. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23(24):4225-4231
32. Poux AN, Cebrat M, Kim CM, et al. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc Natl Acad Sci USA 2002;99(22):14065-14070 (Pubitemid 35257625)
33. Clements A, Marmorstein R. Insights into structure and function of GCN5/PCAF and yEsa 1 histone acetyltransferase domains. Methods Enzymol 2003;371:545-564 (Pubitemid 37542757)
34. Clements A, Rojas JR, Trievel RC, et al. Crystal structure of the histone acetyltransferase domain of the human PCAF transcriptional regulator bound to coenzyme A. EMBO J 1999;18(13):3521-3532 (Pubitemid 29308833)
35. Liu X, Wang L, Zhao K, et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008;451(7180):846-850 (Pubitemid 351253165)
36. Varier RA, Swaminathan V, Balasubramanyam K, Kundu TK. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol 2004;68(6):1215-1220 (Pubitemid 39094287)
37. Balasubramanyam K, Altaf M, Varier RA, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004;279(32):33716-33726 (Pubitemid 39063021)
38. Morinobu A, Biao W, Tanaka S, et al. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum 2008;58(7):2012-2018 (Pubitemid 351988093)
39. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase- dependent chromatin transcription. J Biol Chem 2004;279(49):51163-51171 (Pubitemid 40017859)
40. Marcu MG, Jung YJ, Lee S, et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2006;2(2):169-174 (Pubitemid 44083157)
41. Biel M, Wascholowski V, Giannis A. Epigenetics-an epicenter of gene regulation: histones and histone-modifying enzymes. Angew Chem Int Ed Engl 2005;44(21):3186-3216 (Pubitemid 40778337)
42. Stimson L, Rowlands MG, Newbatt YM, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005;4(10):1521-1532 (Pubitemid 41556434)
43. Mantelingu K, Reddy BA, Swaminathan V, et al. Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol 2007;14(6):645-657 (Pubitemid 46929090)
44. Ornaghi P, Rotili D, Sbardella G, et al. A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. Biochem Pharmacol 2005;70(6):911-917 (Pubitemid 41138856)
45. Mai ARD, Ornaghi P, Tosi F, et al. Identification of small molecules inhibitors of GCN5 histone acetyltransferase activity. J Med Chem 2006;8:24-37 (Pubitemid 43807134)
46. Mai A, Rotili D, Tarantino D, et al. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem 2006;49(23):6897-6907 (Pubitemid 44749755)
47. Smith AT, Livingston MR, Mai A, et al. Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii. Antimicrob Agents Chemother 2007;51(3):1109-1111 (Pubitemid 46355308)
48. Mai ARD, Tarantino D, Nebbioso A, et al. Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorg Med Chem Lett 2009;19(4):1132-1135
49. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;25(3):261-309 (Pubitemid 40489663)
50. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46(24):5097-5116 (Pubitemid 37414179)
51. Mai A, Massa S, Rotili D, et al. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med Chem Lett 2005;15(21):4656-4661 (Pubitemid 41354786)
52. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11(1):77-84 (Pubitemid 40215841)
53. Manzo F, Nebbioso A, Miceli M, et al. TNF-related apoptosis-inducing ligand: Signalling of a 'smart' molecule. Int J Biochem Cell Biol 2007;41(3):460-466
54. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009;41(1):199-213
55. LK-M, inventor. Composition for prevention and/or treatment of cancer. US2008260695; 2008
56. RMIRA, inventor. Turmeric compositions and methods for the preparation there of. WO2008096343A1; 2008
57. DTM, inventor. Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease. WO2008131059A2; 2008
58. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21(21):8370-8377 (Pubitemid 33051435)
59. Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001;22(6):993-1005 (Pubitemid 34070638)
60. SJPUDMC, inventor. Curcumin analogs with anti-tumor and anti-angiogenic properties. US2008234320A1; 2008
61. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008;57(11):1509-1517
62. Funk JL, Oyarzo JN, Frye JB, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 2006;69(3):351-355
63. Jacob A, Wu R, Zhou M, Wang P. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. PPAR Res 2007;2007:89369 (Pubitemid 351171859)
64. Neekv, inventor. Art of preparing derivatives of anacardic acid. US2251547A; 1941
65. Shigehiro TTK, inventor. Carcinogenesis prophylactic. JP2000355536A; 2000
66. Yukihiko KSI, inventor. Antiinflammatory agent. JP2000351728A; 2000
67. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005;70(5):700-713 (Pubitemid 41058705)
68. Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer 2007;31(4):243-305 (Pubitemid 47077491)
69. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23(1A):363-398 (Pubitemid 36361976)
70. Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988;48(21):5941-5946 (Pubitemid 18266780)
71. Huang HC, Jan TR, Yeh SF. Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur J Pharmacol 1992;221(2-3):381-384
72. Sun Y, Jiang X, Chen S, Price BD. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett 2006;580(18):4353-4356 (Pubitemid 44137349)
73. Trevisan MT, Pfundstein B, Haubner R, et al. Characterization of alkyl phenols in cashew (Anacardium occidentale) products and assay of their antioxidant capacity. Food Chem Toxicol 2006;44(2):188-197 (Pubitemid 41773813)
74. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270(42):24995-25000
75. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999;163(6):3474-3483 (Pubitemid 29431852)
76. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999;18(44):6013-6020 (Pubitemid 29535013)
77. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003;278(16):14487-14497 (Pubitemid 36800002)
78. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005;104(4):879-890 (Pubitemid 41113691)
79. Chen X, Hasuma T, Yano Y, et al. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin. Anticancer Res 1997;17(4A):2555-2564 (Pubitemid 27352653)
80. Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett 1994;341(1):19-22 (Pubitemid 24089182)
81. Kim KH, Park HY, Nam JH, et al. The inhibitory effect of curcumin on the growth of human colon cancer cells (HT-29, WiDr) in vitro. Korean J Gastroenterol 2005;45(4):277-284
82. Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 2005;280(26):25284-25290 (Pubitemid 40934623)
83. Youn HS, Saitoh SI, Miyake K, Hwang DH. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 2006;72(1):62-69 (Pubitemid 43810172)
84. Bustanji Y, Taha MO, Almasri IM, et al. Inhibition of glycogen synthase kinase by curcumin: investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J Enzyme Inhib Med Chem 2008;7:1
85. Santel T, Pflug G, Hemdan NY, et al. Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS ONE 2008;3(10):e3508
86. NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 1993;427:1-275
87. Lopez-Lazaro M, Willmore E, Austin CA. Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod 2007;70(5):763-767 (Pubitemid 46953596)
88. Lopez-Lazaro M, Willmore E, Jobson A, et al. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J Nat Prod 2007;70(12):1884-1888
89. Martin-Cordero C, Lopez-Lazaro M, Galvez M, Ayuso MJ. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem 2003;18(6):505-509 (Pubitemid 37493386)
90. Moos PJ, Edes K, Mullally JE, Fitzpatrick FA. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004;25(9):1611-1617 (Pubitemid 39214303)
91. Kishimoto M, Kohno T, Okudela K, et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 2005;11(2 Pt 1):512-519 (Pubitemid 40116874)
92. Yang DI, Yeh CH, Chen S, et al. Neutral sphingomyelinase activation in endothelial and glial cell death induced by amyloid beta-peptide. Neurobiol Dis 2004;17(1):99-107 (Pubitemid 39209317)
93. Wu J, Xie N, Wu Z, et al. Bisubstrate Inhibitors of the MYST HATs Esa1 and Tip60. Bioorg Med Chem 2008;17(3):1381-1386